s
colspan="2" rowspan="1" valign="top"
>10-20
| 10
|
45.5%
|
1
|
20%
|
| 20-30
|
6
|
27.3%
|
4
|
80%
|
| Above 30
|
5
|
22.7%
|
|
|
| Table 9: Showing serum alkaline phosphatase levels in the patients in groups A and B 15 days after treatment
|
| Serum alkaline phosphatase K.A. Units
|
Group A
|
Group B
|
| No. of cases (22)
|
%
|
No. of cases (5)
|
%
|
| 5-10
|
9
|
40.9%
|
|
|
| 10-15
|
6
|
27.3%
|
1
|
20%
|
| 15-20
|
7
|
31.8%
|
4
|
80%
|
| Above 20
|
|
|
|
|
| Table 10: Showing fall in the values of individual liver function tests in groups A and B after 15 days of treatment
|
| Liver Function Tests
|
Fall in values
|
| Group A (22)
|
Group B (5)
|
Serum bilirubin level mgm/100 cc. |
3.5
|
1.3
|
Serum alkaline phosphatase in K.A. Units |
7.5
|
5
|
DISCUSSION
Patrao (1957) and Mathur (1957) reported that Liv.52 helps in improving the outlook in severe hepatic damage. Sheth (1963) observed that it has a salutary effect on anorexia of infective hepatiitis. Qazi (1965) stated that in animal experiments Liv.52 has a good influence on biochemical and functional abnormalities of the liver. He has reported that the drug has a protective action against hepatotoxicity of tetracycline in rats. Arora (1969) reported that Liv.52 adds "materially to patients' comfort and accelerates recovery". According to Jaffari and Shyamraj (1969) Liv.52 clears jaundice earlier, improves appetite and gives a sense of well-being. According to Prasad and Tripathi (1969) the addition of Liv.52 to the therapy brought about an immense increase in appetite and power to assimilate without bowel disturbances in cases of infective hepatitis and malnutrition. Dayal et al., (1971) reported improvement in general condition, regression in jaundice and improvement in liver function tests. They found that inflammatory cells in the liver tissue were less after Liv.52 therapy and recovery was quicker. Prasad and Prasad (1971) reported 85% cure rate while poor response in 15% of cases with Liv.52, in infective hepatitis. Ramalingam et al (1971) reported that in infective hepatitis with the therapy of Liv.52 symptoms improved earlier than in the Vitamin C plus B-complex group, better weight gain was recorded and earlier restoration of liver function to normal observed.
Refference: http://www.himalayahealthcare.com/pdf_files/liv212.pdf
Copyrights © 2009 healthyliver.co.uk
